水热法制备的ZnO纳米线的微结构、光学性质以及光学模型

在90°C的温度环境下,采用水热化学沉积法制备ZnO纳米线薄膜,然后用扫描电子显微镜、透射光谱和X射线衍射等技术对所制备的纳米薄膜进行表征。结果表明,制备的纳米ZnO薄膜的光学带隙在3.274到3.347 eV之间。调节pH值可以控制膜的孔隙率和显微结构。SEM照片清楚地显示两层结构,且这两层的空隙率不同。XRD结果显示(002)取向的优先生长。针对纳米结构的ZnO薄膜建立一个完整的光学模型,包括Bruggeman有效介质近似、粗糙表面的光散射和O’Leary-Johnson-Lim带间吸收模型。利用此光学模型,拟合实验测量的纳米结构ZnO薄膜的透射光谱,拟合结果同实验结果具有很高的一致性。

Inhibitory Effect of Progesterone on Inflammatory Factors After Experimental Traumatic Brain Injury

Objective Traumatic brain injury （TBI） is one of the leading causes of morbidity and mortality in young people. Inflammatory cytokines play an important part in the pathophysiology of TBI. Recent studies demonstrate that progesterone significantly reduces cerebral edema and enhances functional recovery from TBI and stroke in several animal models. This study was designed to investigate the inhibitory effect of progesterone on inflammatory response after traumatic brain injury. Methods Progesterone was injected intraperitoneally using rats as a model of traumatic brain injury, and Western blot technique was applied to detect the expression of three inflammation-related factors： nuclear factor kappa B p65 （NFκB p65）, glial fibrillary acidic protein （GFAP）, and tumor necrosis factor-α （TNF-α）. The water content of injured brain was also examined. A neurological severity score was recorded to evaluate the effect of progesterone on neurodeficit recovery. Results NFκB p65, GFAP, and TNF-α were increased in all injured animals. In rats treated with progesterone, the expression level of NFκB p65 and TNF-α were reduced significantly in comparison with vehicle-treated rats. However, progesterone did not alter the expression of GFAP in the injured rats. Progesterone also reduced the water content of injured brain and the lesion volume. In addition, progesterone-treated injured rats showed significant improvements in the Neurological Severity Score test, compared with vehicle-treated ones. Conclusions Progesterone inhibits the inflammatory response after experimental traumatic brain injury and mitigates the severity of brain damage.

Research on Optical Properties and Micro-processing Characteristics of Collodion Thin Film

Colorless and transparent thin films of collodion are prepared on silicon wafers and K9 optical glass substrates by using spin-coating technique.The visible light transmittance,IR absorption spectra and optical constants of collodion thin film are measured by UV-3501Spectrophotometer,Fourier transform infrared spectrometer(FTIR)and spectroscopic ellipsometry.The measured results show that its average visible light transmittance is 91.9%,and its average infrared absorptivity is better than 0.69/um.In the visible light region,the refractive index of collodion thin film changes in the range of 1.5—1.53,which accords with normal dispersion.The collodion films are etched using oxygen gas plasma.The surface morphology and thickness of etched thin film are measured by the polarizing microscope and MP-100S thickness measurement system,respectively.The results show that the collodion thin film is etched out in the oxygen gas plasma.

Prevalence of wearing-off and dyskinesia among the patients with Parkinson’s disease on levodopa therapy: a multi-center registry survey in China's Mainland

Objective:Chronic levodopa(L-dopa)treatment in Parkinson’s disease(PD)is often associated with the development of motor complications,but the corresponding epidemiological data is rare in Chinese PD patients.The present survey was to investigate the prevalence rate of wearing-off(WO)and dyskinesia among the patients with PD in China.Methods:From May 2012 to October 2012,a 3-step registry survey for wearing off(WO)and dyskinesia patients with PD receiving levodopa therapy was performed simultaneously at 28 movement disorders clinics in China.Results:There were 1,558 PD patients fulfilling the inclusion criteria.Among them,1,051 had at least one positive response of 9-item wearing off questionnaire(WOQ-9),724 and 160 patients were finally diagnosed with WO and dyskinesia by movement disorders specialists,respectively.The overall prevalence rates of WO and dyskinesia were 46.5%(95%CI 44.0%-48.9%)and 10.3%(95%CI 8.8%-11.8%),respectively.The mean score of WOQ-9 for those with WO was 3.8(SD=1.8),with movement slowness being the most common motor symptoms and pain/aching being the most common non-motor symptoms.Better improvement of motor symptoms(n=354,87.8%)and long-term disease control and drug selection(n=288,71.5%)were the two most frequently considered factors when movement disorders specialists adjusted therapeutic strategies for patients with WO.Conclusions:This survey provided the first multi-center epidemiological data of motor complications among PD patients on L-dopa therapy from China's Mainland.WO prevalence rate among Chinese PD patients was in line with,while dyskinesia prevalence rate was lower than previous reports from other Countries.

小P值并不能保证可靠结果:以帕金森病的静息态脑功能成像元分析为例

Thousands of resting state functional magnetic resonance imaging(RS-f MRI)articles have been published on brain disorders.For precise localization of abnormal brain activity,a voxel-level comparison is needed.Because of the large number of voxels in the brain,multiple comparison correction(MCC)must be performed to reduce false positive rates,and a smaller P value(usually including either liberal or stringent MCC)is widely recommended[1].

ncreased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis

Background： High expressions of galectin-3 were identified recently in the end stage of amyotrophic lateral sclerosis （ALS） patients. which suggested that immune reactivity and inflammatory mechanisms might play an important role in the pathogenesis of ALS. The purpose of this study was to investigate plasma galectin-3 levels in different groups and stages of ALS patients and the association with related clinical characteristics. Methods： A total of 51 patients with ALS and 60 normal controls （NCs） were recruited in this study. Plasma galectin-3 levels were determined using the enzyme-linked immunosorbent assay. Patients with ALS were divided into several groups according to their clinical characteristics： gender, type of disease onset, duration of disease, and clinical conditions of disease, Statistical analyses of the differences of galectin-3 levels between groups and the association with the clinical characteristics of disease were performed. Results： As compared with the NCs （201.64 [22.35-401.63] ng/ml）, plasma galectin-3 levels were significantly elevated in the patients with duration 〉 12 months （341.17 [69.12-859.22] ng/ml, P 〈 0.05）, and the patients with limb onset of disease （254.14 [69.12-859.22] ng/m L P 〈 0.05）： however, no difference was found in the patients with duration ≤12 months （250.62 [109.77-334.92] ng/ml, P 〉 0.05）, and the patients with bulbar onset of disease （251.79 [109.20-404.76] ng/ml, P 〉 0.05）. In addition, galectin-3 levels were significantly increased in the female patients （263.27 [123.32-859.22] ng/ml, P 〈 0.05） while no difference was found in the male patients （220.39 [69.12-748.73] ng/ml, P 〉 0.05）. The lhrther statistical analyses showed that plasma galectin-3 levels were positively correlated with the duration of disease （r= 0.293, P 0.037）. Conclusions： Plasma galectin-3 levels were significantly increased in AES patients with limb onset of disease, especially in ALS female patients, and positively correlated with the duration of disease, which suggested that plasma galectin-3 might be an interesting and useful factor associated with ALS.